+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Urokinase Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

  • Report

  • 100 Pages
  • February 2020
  • Region: Global
  • Infinium Global Research
  • ID: 5004972
The report on the global urokinase market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global urokinase market to grow with a CAGR of 78% over the forecast period from 2019-2025. The study on urokinase market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on urokinase market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global urokinase market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global urokinase market over the period of 2017 to 2025. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers
  • Increased risk of pulmonary embolism among the obese population and in people over 60 years

2) Restraints
  • Side effects caused by urokinase such as Urticaria, difficulty in breathing, and swelling of face, lips, tongue, or throat may reduce its adoption

3) Opportunities
  • Ongoing research activities for using urokinase in stroke patients

Research Methodology

A) Primary Research
Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

Our primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered
The global urokinase market is segmented on the basis of type, and application.

The Global Urokinase Market by Type
  • Urokinase Powder
  • Urokinase Solution

The Global Urokinase Market by Application
  • Hospital
  • Clinic
  • Others

Company Profiles

The companies covered in the report include
  • NDPharm
  • Jiangsu Aidea Pharmaceutica
  • Jiangxi Haoran Bio-Pharma
  • Wanhua Biochem
  • ImaRX Therapeutics
  • Taj Pharmaceuticals Ltd
  • 4SC AG
  • Wilex AG
  • Microbix Biosystems Inc.

What does this report deliver?
1. Comprehensive analysis of the global as well as regional markets of the urokinase market.
2. Complete coverage of all the segments in the urokinase market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global urokinase market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
2.1. Urokinase Market Highlights
2.2. Urokinase Market Projection
2.3. Urokinase Market Regional Highlights
3. Global Urokinase Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Type
3.4.2. Growth Matrix Analysis by Application
3.4.3. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Urokinase Market
4. Urokinase Market Macro Indicator Analysis
5. Global Urokinase Market by Type
5.1. Urokinase Powder
5.2. Urokinase Solution
6. Global Urokinase Market by Application
6.1. Hospital
6.2. Clinic
6.3. Others
7. Global Urokinase Market by Region 2019-2025
7.1. North America
7.1.1. North America Urokinase Market by Type
7.1.2. North America Urokinase Market by Application
7.1.3. North America Urokinase Market by Country
7.2. Europe
7.2.1. Europe Urokinase Market by Type
7.2.2. Europe Urokinase Market by Application
7.2.3. Europe Urokinase Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Urokinase Market by Type
7.3.2. Asia-Pacific Urokinase Market by Application
7.3.3. Asia-Pacific Urokinase Market by Country
7.4. RoW
7.4.1. RoW Urokinase Market by Type
7.4.2. RoW Urokinase Market by Application
7.4.3. RoW Urokinase Market by Sub-region
8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Urokinase Market
8.2. Companies Profiled
8.2.1. NDPharm
8.2.2. Jiangsu Aidea Pharmaceutica
8.2.3. Jiangxi Haoran Bio-Pharma
8.2.4. Wanhua Biochem
8.2.5. ImaRX Therapeutics
8.2.7. Taj Pharmaceuticals Ltd
8.2.8. 4SC AG
8.2.9. Wilex AG
8.2.10. Microbix Biosystems Inc.
9. Appendix
9.1. Primary Research Findings and Questionnaire

Companies Mentioned

The companies covered in the report include
  • NDPharm
  • Jiangsu Aidea Pharmaceutica
  • Jiangxi Haoran Bio-Pharma
  • Wanhua Biochem
  • ImaRX Therapeutics
  • Taj Pharmaceuticals Ltd
  • 4SC AG
  • Wilex AG
  • Microbix Biosystems Inc.